Feeding Next‐Generation Nanomedicines to Europe: Regulatory and Quality Challenges

• Published in: Advanced healthcare materials 2023-12, Vol.12 (30), p.e2301956-n/a
• Main Authors: Musazzi, Umberto M., Franzè, Silvia, Condorelli, Fabrizio, Minghetti, Paola, Caliceti, Paolo
• Format: Article
• Language: English
• Subjects: Artificial Intelligence; Europe; Humans; Impact prediction; nanomaterials; Nanomedicine; nanomedicines; Nanotechnology; physicochemical characterization; Prediction models; Quality assurance; quality attribute; Regulatory agencies; regulatory science; Risk assessment
• ISSN: 2192-2640; 2192-2659; 2192-2659
• DOI: 10.1002/adhm.202301956

New and innovative nanomedicines have been developed and marketed over the past half‐century, revolutionizing the prognosis of many human diseases. Although a univocal regulatory definition is not yet available worldwide, the term “nanomedicines” generally identifies medicinal products that use nanotechnology in their design or production. Due to the intrinsic high structural complexity of these products, the scientific and regulatory communities are reflecting on how to revise the regulatory framework to provide a more appropriate benefit/risk balance to authorize them on the market, considering the impact of their peculiar physicochemical features in the evaluation of efficacy and safety patterns. Herein, a critical perspective is provided on the current open issues regarding regulatory qualification and physicochemical characterization of nanosystems considering the current European regulatory framework on nanomedicine products. Practicable paths for improving their quality assurance and predicting their fate in vivo are also argued. Strengthening the multilevel alliance among academic institutions, industrial stakeholders, and regulatory authorities seems strategic to support innovation by standard approaches (e.g., qualification, characterization, risk assessment), and to expand current knowledge, also benefiting from the new opportunities offered by artificial intelligence and digitization in predictive modelling of the impact of nanomedicine characteristics on their fate in vivo. Nanomedicines are revolutionizing the prognosis of many human diseases but their peculiar physicochemical properties are raising new challenges in regulatory approval. Current open issues regarding regulatory qualification and physicochemical characterization of nanosystems are critically discussed, considering the current European regulatory framework on nanomedicine products. Practicable paths for improving their quality assurance and predicting their fate in vivo are also argued.